JP6153336B2 - Tea-derived monoterpene glycoside enzyme and method for using the same - Google Patents

Description

  The present invention relates to a protein having an activity to glycosylate a monoterpene, a polynucleotide encoding the same, a method for producing a monoterpene glycoside using the protein, and a character that highly expresses a monoterpene glycoside The present invention relates to a converter, a monoterpene glycoside prepared by the above method, and use thereof. The present invention also relates to a plant in which the expression of a protein having an activity to glycosylate a monoterpene compound is suppressed and use thereof.

  Terpenoids, especially monoterpenes (C10) and sesquiterpenes (C15), which are relatively low in molecular weight, are the main aroma components of plants and are widely used not only for flavors of food and liquor but also for industrial products such as cosmetics and perfumes. Has been. Monoterpenes such as linalool are synthesized in plant cells, but some are known to accumulate as glycosides.For example, in Arabidopsis thaliana, The body has been reported (Non-patent Document 1). Not only model plants but also industrially important crops such as Asapaceae hop (Humulus lupulus) (Non-patent document 2), Camellia sinensis (Non-patent document 3-6) and Ginger family Zingiber officinale ( It is known that non-patent literature 7) also accumulates monoterpene glycosides. Furthermore, since it has been widely reported to the plant kingdom (Non-patent Document 8), glycosides are considered to be a general form as a precursor of aroma components. Artificial controls such as enzymatically or non-enzymatically cleaving saccharides of terpene glycosides, which are aroma precursors, and volatilizing aroma components are also being studied from an industrial application standpoint (Non-patent Document 9).

  However, although the enzyme (β-primeverosidase) that cuts the sugar of the monoterpene glycoside has been isolated from tea (Non-patent Document 10), sugar is added to the monoterpene. The molecular mechanism (which is glycosylated) is unknown. A comprehensive activity screening of UDP-sugar dependent glycosyltransferase (UDT) in Arabidopsis has reported that some UGT enzymes react with monoterpenes in vitro. The significance of the active role and its activity is not shown (Non-patent Document 11). Since monoterpene glycosides are also accumulated in Citrus sinensis, UGT screening for monoterpenes has been performed, but no active UGT enzyme gene has been identified (Non-patent Document 12). ).

  Camellia sinensis is a tea ingredient that is drunk all over the world, but most of its aroma components are accumulated in glycosides in tea leaves, and endogenous glycosidase of tea during processing. It is known that aroma components represented by monoterpenes are liberated by (hydrolyzing enzyme) (Non-patent Document 13). Β-primeverosidase, a kind of glycosidase, has been isolated (Non-patent Document 10), but the enzyme gene that catalyzes the glycosylation reaction is unknown.

International Publication WO97 / 11184

Aharoni et al (2003) Plant Cell 15, 2866-2884 Kollmannsberger et al (2006) Mschr. Brauwissenschaft 59, 83-89 Guo et al (1994) Biosci. Biotech. Biochem. 58, 1532-1534 Nishikitani et al (1996) Biosci. Biotech. Biochem. 60, 929-931 Moon et al (1996) Biosci. Biotech. Biochem. 60, 1815-1819 Ma et al (2001) Phytochemisty 56, 819-825 Sekiwa et al (1999) Biosci. Biotech. Biochem. 63, 384-389 Winterhalter and Skouroumounis (1997) Adv. Biochem. Eng. Biotechnol. 55, 73-105 Herman (2007) Angew. Chem. Int. Ed. 46, 5836-5863 Mizutani et al (2002) Plant Physiol. 130, 2164-2176 Caputi et al (2008) Chem. Eur. J. 14, 6656-6662 Fan et al (2010) Genome 53, 816-823 Wang, D., et al (2000) J. Agric. Food Chem. 48, 5411-5418 Kannangara et al (2011) THE PLANT JOURNAL, Volume 68, Issue 2, October Pages: 287-301

  As a result of intensive studies, the present inventors have succeeded in identifying an enzyme that catalyzes a glycosylation reaction of a monoterpene and a gene sequence encoding the enzyme in tea. The present invention is based on the above findings.

That is, the present invention is as follows.
[1] The protein according to any one of the following (a) to (c) selected from the group consisting of:
(A) a protein comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10;
(B) the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10, consisting of an amino acid sequence in which 1 to 95 amino acids are deleted, substituted, inserted and / or added, and having an activity of glycosylating a monoterpene compound A protein having;
(C) a protein having an amino acid sequence having a sequence identity of 80% or more with respect to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10 and having an activity to glycosylate a monoterpene compound [2] The monoterpene The protein according to [1] above, wherein the compound is geraniol or linalool.
[3] A polynucleotide selected from the group consisting of the following (a) to (e).
(A) a polynucleotide comprising the base sequence of SEQ ID NO: 1 or SEQ ID NO: 9;
(B) a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10;
(C) The amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10 consists of an amino acid sequence in which 1 to 95 amino acids are deleted, substituted, inserted, and / or added, and glycosylated monoterpene compound A polynucleotide encoding a protein having activity;
(D) a polyprotein encoding a protein having an amino acid sequence having a sequence identity of 80% or more with respect to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10 and having an activity to glycosylate a monoterpene compound nucleotide;
(E) A polynucleotide that hybridizes with a polynucleotide comprising a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 9 under highly stringent conditions, and has an activity to glycosylate a monoterpene compound [4] A non-human transformant into which the polynucleotide according to [3] has been introduced.
[5] The transformant according to [4] above, wherein the polynucleotide is inserted into an expression vector.
[6] The transformant according to [4], which is a plant.
[7] The extract of the transformant according to [4].
[8] A food, a fragrance, a pharmaceutical or an industrial raw material containing the extract according to [7].
[9] A method for producing a protein having an activity to glycosylate a monoterpene compound, wherein the non-human transformant according to [4] is cultured.
[10] A method for producing a monoterpene glycoside, comprising the step of reacting the protein according to [1], a UDP-sugar, and a monoterpene compound to glycosylate the monoterpene compound.
[11] The method according to [10], wherein the UDP-sugar is UDP-glucose.
[12] The method according to [10], wherein the monoterpene compound is geraniol or linalool.

  By using the protein of the present invention and the polynucleotide encoding the protein, a glycoside of a terpene compound can be produced with high efficiency. Further, since the transformant of the present invention has a high content of terpene compound glycosides, terpene compound glycosides can be efficiently extracted and purified from these transformants.

The result (SDS-PAGE) of the recombinant protein expression of tea-derived CsUGT30 is shown. Fig. 3 shows glycosylation activity of tea-derived CsUGT30 recombinant protein. The result (SDS-PAGE) of the recombinant protein expression of tea-derived CsUGT-C1 is shown. The glycosylation activity of the tea-derived CsUGT-C1 recombinant protein is shown.

Hereinafter, the present invention will be described in detail. The following embodiment is an example for explaining the present invention, and is not intended to limit the present invention to this embodiment alone. The present invention can be implemented in various forms without departing from the gist thereof.
It should be noted that all documents cited in the present specification, as well as published publications, patent gazettes, and other patent documents are incorporated herein by reference. In addition, this specification includes the contents described in the specification and drawings of the Japanese patent application (Japanese Patent Application No. 2012-022983), which is the basis of the priority claim of the present application filed on February 6, 2012.

The present inventors have elucidated for the first time that the enzyme proteins responsible for glycosylation of the tea monoterpene compound are CsUGT30 and CsUGT-C1. The CDS sequence and deduced amino acid sequence of CsUGT30 are SEQ ID NOs: 1 and 2, respectively, and the CDS sequence and deduced amino acid sequence of CsUGT-C1 are SEQ ID NOs: 9 and 10, respectively.
These polynucleotides and enzymes can be obtained by the techniques described in the examples below, known genetic engineering techniques, known synthesis techniques, and the like.

1. Tea-derived monoterpene glycoside enzyme The present invention provides a protein according to any one selected from the group consisting of the following (a) to (c) (hereinafter referred to as “protein of the present invention”): .
(A) a protein comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10;
(B) the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10, consisting of an amino acid sequence in which 1 to 95 amino acids are deleted, substituted, inserted and / or added, and having an activity of glycosylating a monoterpene compound A protein having;
(C) a protein having an amino acid sequence having a sequence identity of 80% or more with respect to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10, and having an activity to glycosylate a monoterpene compound

  The protein described in (b) or (c) above is typically a naturally occurring variant of the polypeptide of SEQ ID NO: 2 or SEQ ID NO: 10, for example, “Sambrook & Russell, Molecular Cloning: A Laboratory Manual Vol. 3, Cold Spring Harbor Laboratory Press 2001 "," Ausubel, Current Protocols in Molecular Biology, John Wiley & Sons 1987-1997 "," Nuc. Acids. Res., 10, 6487 (1982) "," Proc. Natl. Acad. Sci. USA, 79, 6409 (1982) "," Gene, 34, 315 (1985) "," Nuc. Acids. Res., 13, 4431 (1985) "," Proc. Natl. Acad. Sci. USA, 82, 488 (1985) "and the like can also be obtained artificially using the site-directed mutagenesis method described.

  In the present specification, “in the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10, which comprises an amino acid sequence in which 1 to 95 amino acids are deleted, substituted, inserted, and / or added, and glycosylated monoterpene compound As the `` protein having activity to form '', in the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10, for example, 1 to 95, 1 to 90, 1 to 85, 1 to 80, 1 to 75, 1-70, 1-65, 1-60, 1-55, 1-50, 1-49, 1-48, 1-47, 1-46, 1-45, 1 to 44, 1 to 43, 1 to 42, 1 to 41, 1 to 40, 1 to 39, 1 to 38, 1 to 37, 1 to 36, 1 to 35, 1 to 34, 1 to 33, 1 to 32, 1 to 31, 1 to 30, 1 to 29, 1 to 28, 1 to 27, 1 to 26, 1 to 25, 1-24, 1-23, 1-22, 1-21, 1-20, 1-19, 1-18, 1-17, 1-16, 1-15, 1-14, 1-13, 1-12, 1-11, 1-10, 1-9 (1 to several), 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, or 1 amino acid residue Examples thereof include a protein consisting of an amino acid sequence deleted, substituted, inserted and / or added and having an activity to glycosylate a monoterpene compound. In general, the smaller the number of amino acid residue deletions, substitutions, insertions and / or additions, the better.

  Such proteins include the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10 and 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% More than 88%, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.1% or more, 99.2% or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more amino acid sequences having sequence identity and mono Examples thereof include proteins having an activity of glycosylated terpene compound. In general, the larger the sequence identity value, the better.

  Here, the “activity for glycosylating a monoterpene compound” means an activity of adding a sugar contained in a UDP sugar to a hydroxy group of a monoterpene compound which is an aglycone (glycosylation). The hydroxy group to which the sugar is added is not particularly limited.

  The activity of glycosylating a monoterpene compound is 1 to 500 ng (preferably 50 to 200 ng, most preferably 100 ng) of the protein of the present invention, 1 to 1000 μM of UDP sugar (for example, UDP-glucose) ( Preferably pH 100 containing 100-700 μM, most preferably 500 μM) and monoterpene compounds (eg linalool or geraniol) 1-500 μM (preferably 100-500 μM, most preferably 250 μM). After incubating at a temperature of 20 to 40 ° C. in a buffer solution in a neutral region (for example, sodium phosphate buffer or potassium phosphate buffer) of -8.0, the monoterpene is purified, and the purified monoterpene is converted to LC- It can confirm by analyzing by well-known methods, such as MS analysis (Liquid Chromatography-Mass Spectrometry).

  The glycosylation reaction is generally completed in about 1 minute to 12 hours.

  The deletion, substitution, insertion and / or addition of one or more amino acid residues in the amino acid sequence of the protein of the present invention means that one or more amino acid residues in the same sequence are at one or more positions in the amino acid sequence. It means that there are deletion, substitution, insertion and / or addition of a plurality of amino acid residues, and two or more of deletion, substitution, insertion and addition may occur simultaneously.

  Examples of amino acid residues that can be substituted with each other are shown below. Amino acid residues contained in the same group can be substituted for each other. Group A: leucine, isoleucine, norleucine, valine, norvaline, alanine, 2-aminobutanoic acid, methionine, o-methylserine, t-butylglycine, t-butylalanine, cyclohexylalanine; Group B: aspartic acid, glutamic acid, isoaspartic acid , Isoglutamic acid, 2-aminoadipic acid, 2-aminosuberic acid; group C: asparagine, glutamine; group D: lysine, arginine, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid; group E : Proline, 3-hydroxyproline, 4-hydroxyproline; Group F: serine, threonine, homoserine; Group G: phenylalanine, tyrosine.

  The protein of the present invention can be obtained by expressing a polynucleotide encoding the same (see “polynucleotide of the present invention” described later) in an appropriate host cell, but the Fmoc method (fluorenylmethyloxy) is used. It can also be produced by a chemical synthesis method such as a carbonyl method) or a tBoc method (t-butyloxycarbonyl method). Alternatively, chemical synthesis can be performed using a peptide synthesizer such as Advanced Automation Peptide Protein Technologies, Perkin Elmer, Protein Technologies, PerSeptive, Applied Biosystems, or SHIMADZU.

In the present invention, “monoterpene compound” means isoprene.

In addition to biological materials produced by plants, insects, fungi, and the like, chemically synthesized compounds are also included.
In the present invention, the monoterpene compound is not particularly limited as long as it has a hydroxy group (for example, hydroxy monoterpenoid).
Examples of such monoterpenes include, but are not limited to, nerol, geraniol, and linalool. Geraniol or linalool is preferred.

For example, geraniol derived from tea has an —OH group at the 1-position and linalool has an —OH group at the 3-position. Thus, when geraniol contained in tea cells is glycosylated using the protein of the present invention, a sugar is added to the 1-OH group. In addition, when linalool contained in tea cells is glycosylated using the protein of the present invention, a sugar is added to the 3-OH group.

  In the present invention, “UDP-sugar” is a uridine diphosphate (UDP) -linked sugar, and examples include, but are not limited to, UDP-glucuronic acid and UDP-glucose. It is not something. Preferably, the UDP-sugar is UDP-glucose.

2． Method for Producing Monoterpene Glycoside The present invention makes it possible to produce monoterpene glycosides easily and in large quantities by utilizing the glycosylation activity of monoterpene compounds possessed by proteins.
Therefore, in another embodiment, the present invention provides a glycoside of a monoterpene compound, comprising the step of reacting the protein of the present invention, a UDP sugar, and a monoterpene compound to convert the monoterpene compound into a glycoside. A method for manufacturing a body is provided.

  In the method for producing a monoterpene glycoside of the present invention, a preferred example of the UDP-sugar is UDP glucose, and the monoterpene compound is preferably geraniol or linalool.

  The method for producing a monoterpene glycoside according to the present invention includes a step of reacting the protein of the present invention with a UDP sugar and a monoterpene compound to convert the monoterpene compound into a glycoside. The method of the present invention may further include a step of purifying the glycoside of the monoterpene compound produced in the above step.

  Glycosides of monoterpene compounds are extracted with an appropriate solvent (aqueous solvent such as water or organic solvent such as alcohol, ether and acetone), ethyl acetate and other organic solvents: water gradient, high performance liquid chromatography (High Performance Liquid Chromatography (HPLC), gas chromatography, time-of-flight mass spectrometry (TOF-MS), Ultra (High) Performance Liquid chromatography (UPLC), etc. It can be purified by the method.

3． A monoterpene glycoside-rich non-human transformant monoterpene glycoside is produced in cells of bacteria (such as Escherichia coli or yeast), plants, insects, and mammals other than humans using the protein of the present invention. You can also. This is because the protein of the present invention is an enzyme derived from tea or a variant thereof, and is therefore expected to have high activity even in an intracellular environment. In this case, the polynucleotide encoding the protein of the present invention (see “polynucleotide of the present invention” described later) is introduced into host cells derived from bacteria, plants, insects, mammals other than humans, etc. A monoterpene glycoside can be produced by reacting the protein of the present invention with the UDP-sugar and monoterpene compound present in the cells.

Therefore, the present invention provides a non-human transformant into which a polynucleotide according to any one selected from the group consisting of the following (a) to (e) (hereinafter referred to as “polynucleotide of the present invention”) is introduced ( Hereinafter, the “transformant of the present invention”) is provided.
(A) a polynucleotide comprising the base sequence of SEQ ID NO: 1 or SEQ ID NO: 9;
(B) a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10;
(C) The amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10 consists of an amino acid sequence in which 1 to 95 amino acids are deleted, substituted, inserted, and / or added, and glycosylated monoterpene compound A polynucleotide encoding a protein having activity;
(D) a polyprotein encoding a protein having an amino acid sequence having a sequence identity of 80% or more with respect to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10 and having an activity to glycosylate a monoterpene compound And (e) a polynucleotide that hybridizes under high stringency conditions with a polynucleotide comprising a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 9, wherein the monoterpene compound is a glycoside. Polynucleotide encoding protein having activity to convert

  In the present specification, “polynucleotide” means DNA or RNA.

  In the present specification, “polynucleotide hybridizing under highly stringent conditions” means, for example, a polynucleotide comprising a base sequence complementary to the base sequence of SEQ ID NO: 1 or SEQ ID NO: 9, or SEQ ID NO: 2 or A polynucleotide obtained by using a colony hybridization method, a plaque hybridization method, a southern hybridization method, or the like using as a probe all or part of a polynucleotide comprising the base sequence encoding the amino acid sequence of SEQ ID NO: 10. Examples of hybridization methods include "Sambrook & Russell, Molecular Cloning: A Laboratory Manual Vol. 3, Cold Spring Harbor, Laboratory Press 2001" and "Ausubel, Current Protocols in Molecular Biology, John Wiley & Sons 1987-1997". Can be used.

  In the present specification, “high stringent conditions” means, for example, (1) 5 × SSC, 5 × Denhardt's solution, 0.5% SDS, 50% formamide, 50 ° C., (2) 0.2 × SSC, 0.1% SDS , 60 ℃, (3) 0.2 x SSC, 0.1% SDS, 62 ℃, (4) 0.2 x SSC, 0.1% SDS, 65 ℃, or (5) 0.1x SSC, 0.1% SDS, 65 ℃ However, the present invention is not limited to this. Under these conditions, it can be expected that DNA having higher sequence identity can be efficiently obtained as the temperature is increased. However, factors affecting the stringency of hybridization include multiple factors such as temperature, probe concentration, probe length, ionic strength, time, and salt concentration, and those skilled in the art can select these factors as appropriate. By doing so, it is possible to achieve the same stringency.

  In addition, when using a commercially available kit for hybridization, for example, Alkphos Direct Labeling and Detection System (GE Healthcare) can be used. In this case, follow the protocol attached to the kit and incubate with the labeled probe overnight, then place the membrane in the primary wash buffer containing 0.1% (w / v) SDS at 55-60 ° C. After washing, the hybridized DNA can be detected. Alternatively, when preparing a probe based on the base sequence complementary to the base sequence of SEQ ID NO: 1 or SEQ ID NO: 9, or the base sequence encoding the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10, When the probe is labeled with digoxigenin (DIG) using a commercially available reagent (for example, PCR labeling mix (Roche Diagnostics)), a DIG nucleic acid detection kit (Roche Diagnostics) is used. Hybridization can be detected.

  As a polynucleotide other than the above, the DNA of SEQ ID NO: 1 or SEQ ID NO: 9, or SEQ ID NO: 2 or SEQ ID NO: 4, when calculated using homology search software such as FASTA and BLAST using default parameters 60% or more, 61% or more, 62% or more, 63% or more, 64% or more, 65% or more, 66% or more, 67% or more, 68% or more, 69% or more, with DNA encoding the amino acid sequence of number 10 70% or more, 71% or more, 72% or more, 73% or more, 74% or more, 75% or more, 76% or more, 77% or more, 78% or more, 79% or more, 80% or more, 81% or more, 82% 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.1% or more, 99.2% or more, 99.3% or more, 99.4% or more, 99.5% or more, 99. Examples thereof include DNA having sequence identity of 6% or more, 99.7% or more, 99.8% or more, or 99.9% or more.

  The sequence identity of amino acid sequences and nucleotide sequences is determined by FASTA (Science 227 (4693): 1435-1441, (1985)) or the algorithm BLAST (Basic Local Alignment Search Tool) by Carlin and Arthur (Proc. Natl. Acad. Sci. USA 872264-2268, 1990; Proc Natl Acad Sci USA 90: 5873, 1993). Programs called blastn, blastx, blastp, tblastn and tblastx based on the BLAST algorithm have been developed (Altschul SF, et al: J Mol Biol 215: 403, 1990). When analyzing a base sequence using blastn, parameters are set to, for example, score = 100 and wordlength = 12. When analyzing an amino acid sequence using blastp, the parameters are set to, for example, score = 50 and wordlength = 3. When using BLAST and Gapped BLAST programs, the default parameters of each program are used.

  The polynucleotide of the present invention described above can be obtained by a known genetic engineering technique or a known synthesis technique.

  The polynucleotide of the present invention is preferably introduced into a host while being inserted into an appropriate expression vector.

Suitable expression vectors are usually
(I) a promoter capable of being transcribed in a host cell;
(Ii) a polynucleotide of the present invention linked to the promoter; and (iii) an expression cassette comprising, as a component, a signal that functions in a host cell with respect to transcription termination and polyadenylation of an RNA molecule. .

  As a method for producing an expression vector, a method using a plasmid, phage, cosmid or the like can be mentioned, but it is not particularly limited.

  The specific type of vector is not particularly limited, and a vector that can be expressed in a host cell can be appropriately selected. That is, according to the type of the host cell, a promoter sequence is appropriately selected in order to reliably express the polynucleotide of the present invention, and a vector in which this and the polynucleotide of the present invention are incorporated into various plasmids or the like is used as an expression vector. Good.

  The expression vector of the present invention contains an expression control region (for example, a promoter, a terminator and / or an origin of replication) depending on the type of host to be introduced. Conventional promoters (eg, trc promoter, tac promoter, lac promoter, etc.) are used as promoters for bacterial expression vectors. Examples of yeast promoters include glyceraldehyde 3-phosphate dehydrogenase promoter, PH05 promoter, etc. Examples of the promoter for filamentous fungi include amylase and trpC. Examples of promoters for expressing a target gene in plant cells include the cauliflower mosaic virus 35S RNA promoter, rd29A gene promoter, rbcS promoter, and the enhancer sequence of the cauliflower mosaic virus 35S RNA promoter derived from Agrobacterium. And the mac-1 promoter added to the 5 ′ side of the mannopine synthase promoter sequence. Examples of animal cell host promoters include viral promoters (eg, SV40 early promoter, SV40 late promoter, etc.).

  The expression vector preferably contains at least one selectable marker. Such markers include auxotrophic markers (ura5, niaD), drug resistance markers (hygromycine, zeocin), geneticin resistance gene (G418r), copper resistance gene (CUP1) (Marin et al., Proc. Natl. Acad Sci. USA, vol. 81, p. 337, 1984), cerulenin resistance gene (fas2m, PDR4) (respectively, Minoru Ogura et al., Biochemistry, vol. 64, p. 660, 1992; Hussain et al., Gene, vol. 101, p. 149, 1991) can be used.

  The production method (production method) of the transformant of the present invention is not particularly limited, and examples thereof include a method of transforming by introducing an expression vector containing the polynucleotide of the present invention into a host. The host cell used here is not particularly limited, and various conventionally known cells can be suitably used. Specific examples include bacteria such as Escherichia coli, yeast (budding yeast Saccharomyces cerevisiae, fission yeast Schizosaccharomyces pombe), plant cells, and animal cells other than humans.

  Appropriate culture media and conditions for the above-described host cells are well known in the art. In addition, the organism to be transformed is not particularly limited, and examples thereof include various microorganisms exemplified for the host cells, animals other than plants or animals.

  As a method for transforming a host cell, a publicly known method can be used. For example, electroporation method (Mackenxie, DA et al., Appl. Environ. Microbiol., Vol. 66, p. 4655-4661, 2000), particle delivery method (Japanese Patent Laid-Open No. 2005-287403, “Method of Breeding Lipid-Producing Bacteria” ), Spheroplast method (Proc. Natl. Acad. Sci. USA, vol. 75, p. 1929, 1978), lithium acetate method (J. Bacteriology, vol. 153, p. 163, 1983) ), Methods in yeast genetics, 2000 Edition: A method described in A Cold Spring Harbor Laboratory Course Manual), but is not limited thereto.

  For other general molecular biology methods, see "Sambrook & Russell, Molecular Cloning: A Laboratory Manual Vol. 3, Cold Spring Harbor Laboratory Press 2001", "Methods in Yeast Genetics, A laboratory manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) ".

In one embodiment of the present invention, the transformant can be a plant transformant. The plant transformant according to this embodiment is obtained by introducing a recombinant vector containing the polynucleotide according to the present invention into a plant so that the polypeptide encoded by the polynucleotide can be expressed.

  When a recombinant expression vector is used, the recombinant expression vector used for transformation of the plant body is not particularly limited as long as it is a vector capable of expressing the polynucleotide according to the present invention in the plant. Examples of such a vector include a vector having a promoter that constitutively expresses a polynucleotide in a plant cell or a vector having a promoter that is inducibly activated by an external stimulus.

  Examples of promoters that constitutively express polynucleotides in plant cells include cauliflower mosaic virus 35S RNA promoter, rd29A gene promoter, rbcS promoter, mac-1 promoter, and the like.

  Examples of promoters that are inducibly activated by external stimuli include mouse mammary tumor virus (MMTV) promoter, tetracycline responsive promoter, metallothionein promoter, heat shock protein promoter, and the like.

  Plants to be transformed in the present invention include whole plants, plant organs (eg leaves, petals, stems, roots, seeds, etc.), plant tissues (eg epidermis, phloem, soft tissue, xylem, vascular bundle, It means any of a palisade tissue, a spongy tissue, etc.) or a plant culture cell, or various forms of plant cells (eg, suspension culture cells), protoplasts, leaf sections, callus, and the like. The plant used for transformation is not particularly limited, and may be any plant belonging to the monocotyledonous plant class or the dicotyledonous plant class.

  For the introduction of genes into plants, transformation methods known to those skilled in the art (for example, Agrobacterium method, gene gun method, PEG method, electroporation method, etc.) are used. For example, a method using Agrobacterium and a method for directly introducing it into plant cells are well known. When the Agrobacterium method is used, the constructed plant expression vector is introduced into an appropriate Agrobacterium (for example, Agrobacterium tumefaciens), and this strain is introduced into the leaf disk method (Hirofumi Uchimiya). Author, Plant Gene Manipulation Manual (1990), pp. 27-31, Kodansha Scientific, Tokyo) and the like can be used to infect sterile cultured leaf pieces to obtain transformed plants. The method of Nagel et al (Micribiol. Lett., 67: 325 (1990)) can also be used. In this method, for example, an expression vector is first introduced into Agrobacterium, and then transformed Agrobacterium is transformed into plant cells by the method described in Plant Molecular Biology Manual (Gelvin, SB et al., Academic Press Publishers). Or it is the method of introduce | transducing into a plant tissue. Here, “plant tissue” includes callus obtained by culturing plant cells. In the case of performing transformation using the Agrobacterium method, a binary vector (such as pBI121 or pPZP202) can be used.

  As a method for directly introducing a gene into a plant cell or plant tissue, an electroporation method or a particle gun method is known. When using a particle gun, a plant body, a plant organ, or a plant tissue itself may be used as it is, or may be used after preparing a section, or a protoplast may be prepared and used. The sample thus prepared can be processed using a gene transfer apparatus (for example, PDS-1000 (BIO-RAD)). Treatment conditions vary depending on the plant or sample, but are usually performed at a pressure of about 450 to 2000 psi and a distance of about 4 to 12 cm.

  A cell or plant tissue into which a gene has been introduced is first selected for drug resistance such as hygromycin resistance, and then regenerated into a plant by a conventional method. Regeneration of a plant body from a transformed cell can be performed by a method known to those skilled in the art depending on the type of plant cell.

  When plant cultured cells are used as a host, transformation is carried out by introducing a recombinant vector into the cultured cells using a gene gun, electroporation method or the like. Callus, shoots, hairy roots, etc. obtained as a result of transformation can be used as they are for cell culture, tissue culture or organ culture, and can be used at a suitable concentration using conventionally known plant tissue culture methods. It can be regenerated into plants by administration of plant hormones (auxin, cytokinin, gibberellin, abscisic acid, ethylene, brassinolide, etc.).

  Whether or not the polynucleotide of the present invention has been introduced into a plant can be confirmed by PCR, Southern hybridization, Northern hybridization, or the like. For example, DNA is prepared from a transformed plant, PCR is performed by designing DNA-specific primers. PCR can be performed under the same conditions as those used for preparing the plasmid. After that, the amplified product is subjected to agarose gel electrophoresis, polyacrylamide gel electrophoresis or capillary electrophoresis, stained with ethidium bromide, SYBR Green solution, etc., and the amplified product is detected as a single band, It can be confirmed that it has been transformed. Moreover, PCR can be performed using a primer previously labeled with a fluorescent dye or the like to detect an amplification product. Furthermore, it is possible to employ a method in which the amplification product is bound to a solid phase such as a microplate and the amplification product is confirmed by fluorescence or enzyme reaction.

  Once a transformed plant in which the polynucleotide of the present invention is integrated into the genome is obtained, offspring can be obtained by sexual or asexual reproduction of the plant. Further, for example, seeds, fruits, cuttings, tubers, tuberous roots, strains, callus, protoplasts, etc. can be obtained from the plant or its progeny, or clones thereof, and the plant can be mass-produced based on them. it can. Therefore, the present invention also includes a plant body into which the polynucleotide according to the present invention is introduced so that it can be expressed, or a progeny of the plant body having the same properties as the plant body, or a tissue derived therefrom.

  In addition, transformation methods for various plants have already been reported. Examples of the transformant plant according to the present invention include solanaceous plants (eg, eggplant, tomato, capsicum, potato, tobacco, datura, physalis, petunia, calibracore, nilenbergia, etc.), legumes (eg, soybean, azuki bean, Peanuts, common bean, broad bean, Miyakogusa, etc.), rose family plants (eg, strawberry, ume, cherry, rose, blueberry, blackberry, bilberry, cassis, raspberry, etc.), dianthus plants (carnation, gypsophila, etc.), asteraceae plants (Chrysanthemum, gerbera, sunflower, daisy, etc.), Orchidaceae (Orchid, etc.), Primula (Cyclamen, etc.), Gentianaceae (Eustoma, Gentian), Iridaceae (Freesia, Ayame, Gladiolus, etc.) Family plant (Antirrhinum majus) , Torenia, etc.) Bensyiso (Kalanchoe), liliaceae (lily, tulip, etc.), convolvulaceae (egagao, maple convolvulus, jorgao, sweet potato, rucos, Evolvulus, etc.), hydrangea family (hydrangea, peony etc.), cucurbitaceae Plants (Lepidoptera, etc.), Cranaceae plants (Pelargonium, Geranium, etc.), Spiraceae plants (Forsythia, etc.), Grapeaceous plants (eg, grapes, etc.), Camelliaaceae plants (Cha, Camellia, Camellia, etc.), Gramineae plants ( For example, rice, barley, wheat, oat, rye, corn, millet, mackerel, sugarcane, bamboo, oats, millet, sorghum, sorghum, pearl barley, grass, etc. Asa, etc.), Rubiaceae (Coffea, Kuchina) Etc.), beech plants (eg, oak, beech, oak), sesame plants (eg, sesame), citrus plants (eg, Daidai, Yuzu, Satsuma mandarin, salamander) and cruciferous plants (red cabbage, ha button, radish) , White cruciferous, oilseed rape, cabbage, broccoli, cauliflower, etc.) and Lamiaceae (eg, salvia, perilla, lavender, seaweed). Preferable examples of the plant include aromatic plants such as perilla and lavender, etc., or horticultural plants that do not originally have much aroma but have high commercial value, such as carnation.

  The plant transformed with the polynucleotide of the present invention (hereinafter “the plant of the present invention” or “the plant of the present invention”) contains more glycosides of the monoterpene compound than its wild type.

  The plant of the present invention can easily obtain a complete plant body by growing seeds, cuttings, bulbs and the like of the plant of the present invention.

  Therefore, the plant of the present invention includes the whole plant body, plant organs (for example, leaves, petals, stems, roots, seeds, bulbs, etc.), plant tissues (for example, epidermis, phloem, soft tissue, xylem, vascular bundle, fences) Tissue, spongy tissue, etc.) or plant culture cells, or various forms of plant cells (eg, suspension culture cells), protoplasts, leaf sections, callus, and the like.

4. Extract of transformant and use thereof In another embodiment, the present invention also provides an extract of the transformant described above. Since the transformant of the present invention has a higher monoterpene glycoside content than its wild type, the extract is considered to contain a high concentration of monoterpene glycoside.

  The extract of the transformant of the present invention can be obtained by crushing the transformant using glass beads, a homogenizer, a sonicator or the like, centrifuging the crushed material, and collecting the supernatant. it can. Furthermore, you may give the further extraction process by the extraction method of monoterpene glycoside mentioned above.

  The extract of the transformant of the present invention can be used for applications such as production of foods, fragrances, pharmaceuticals, and industrial raw materials (raw materials such as cosmetics and soaps) according to a conventional method.

  In another embodiment, the present invention also provides foods, fragrances, medicines, and industrial raw materials (raw materials such as cosmetics and soaps) containing the extract of the transformant of the present invention. Preparation of foods, fragrances, pharmaceuticals, and industrial raw materials containing the extract of the transformant of the present invention is according to a conventional method. Thus, the foodstuffs, fragrance | flavor, pharmaceutical, industrial raw material, etc. which contain the extract of the transformant of this invention contain the monoterpene glycoside produced | generated using the transformant of this invention.

  The dosage form of the fragrance | flavor (composition) or pharmaceutical (composition) of this invention is not specifically limited, Arbitrary dosage forms, such as solution form, paste form, gel form, solid form, and powder form, can be taken. Further, the perfume composition or pharmaceutical composition of the present invention is an oil, lotion, cream, emulsion, gel, shampoo, hair rinse, hair conditioner, enamel, foundation, lipstick, funny, pack, ointment, perfume, powder, eau de cologne, In addition to cosmetics such as toothpastes, soaps, aerosols, cleansing foams, or external preparations for skin, they can be used for bath preparations, hair nourishing agents, skin cosmetics, sunscreen agents, and the like.

  The cosmetic composition of the present invention may further contain other fats and oils and / or dyes, fragrances, preservatives, surfactants, pigments, antioxidants and the like as necessary. These blending ratios can be appropriately determined by those skilled in the art according to the purpose (for example, fats and oils in the composition are 1 to 99.99% by weight, preferably 5 to 99.99% by weight, more preferably 10 to 99.95). % May be contained). The pharmaceutical composition of the present invention may further contain other pharmaceutically active ingredients (for example, anti-inflammatory ingredients) or auxiliary ingredients (for example, lubricating ingredients, carrier ingredients) as necessary.

Examples of the food of the present invention include nutritional supplements, health foods, functional foods, infant foods, elderly foods, and the like. In the present specification, food is a generic term for solids, fluids, liquids, and mixtures thereof that can be consumed.
Nutritional supplements refer to foods that are enriched with specific nutritional components. Healthy food means food that is considered healthy or healthy, and includes nutritional supplements, natural foods, diet foods, and the like. Functional food means food for replenishing nutritional components that fulfill the body's regulatory functions, and is synonymous with food for specified health use. Infant food is food that is given to children up to about 6 years of age. The food for the elderly refers to food that has been processed so that it can be easily digested and absorbed as compared to untreated food.

  Examples of these food forms include bread, noodles, rice, confectionery (candy, chewing gum, gummi, tablet confectionery, Japanese confectionery), agricultural products such as tofu and processed products thereof, sake, medicinal liquor, mirin, vinegar, Fermented foods such as soy sauce and miso, livestock foods such as yogurt, ham, bacon, sausage, marine foods such as kamaboko, fried tempura, hampen, fruit juice drinks, soft drinks, sports drinks, alcoholic drinks, tea etc. or seasonings May be.

Five. Glycosylation of monoterpenes is inhibited by suppressing the expression of proteins that have the ability to glycosidate monoterpene compounds that are endogenously present in plant plants in which the expression of monoterpene glycosides is suppressed Is done. As a result, in the said plant, more monoterpenes will exist as an aglycon, and it can be anticipated that a stronger fragrance is emitted.

  Therefore, the present invention provides a plant in which the expression of a protein having an activity to glycosylate a monoterpene compound is suppressed.

Specifically, a protein having an activity to glycosylate a monoterpene compound (hereinafter referred to as “monoterpene glycoside enzyme”) is any one selected from the group consisting of the following (a) to (e) Is encoded by the polynucleotide described in 1.
(A) a polynucleotide comprising the base sequence of SEQ ID NO: 1 or SEQ ID NO: 9;
(B) a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10;
(C) The amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10 consists of an amino acid sequence in which 1 to 95 amino acids are deleted, substituted, inserted, and / or added, and glycosylated monoterpene compound A polynucleotide encoding a protein having activity;
(D) a polyprotein encoding a protein having an amino acid sequence having a sequence identity of 80% or more with respect to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10 and having an activity to glycosylate a monoterpene compound And (e) a polynucleotide that hybridizes under high stringency conditions with a polynucleotide comprising a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 9, wherein the monoterpene compound is a glycoside. Polynucleotide encoding protein having activity to convert

  The definition and the like of the polynucleotides (a) to (e) are as described in “3. Non-human transformant having a high monoterpene glycoside content”.

  Specific examples of the method for suppressing the expression of monoterpene glucosylase include substances that reduce the expression level of messenger RNA (mRNA) of the enzyme, such as low molecular weight compounds, hormones, proteins, and nucleic acids. In one embodiment, the nucleic acid suppresses the function or expression of a gene encoding the enzyme. Examples of such nucleic acids include siRNA for RNA interference (RNAi) (small interfering RNA, hairpin shRNA (Short Hairpin RNA), double-stranded RNA (Double Stranded RNA: dsRNA), antisense nucleic acid , Decoy nucleic acid, aptamer, etc. These inhibitory nucleic acids can suppress the expression of the above gene.The monoterpene glycoside enzyme gene to be inhibited is the above (a) to In the present invention, not only the coding region of the monoterpene glycoside enzyme gene but also the non-coding region can be used as the inhibition target region. Is possible.

  RNA interference (RNAi) is a multi-step process that takes place in multiple stages. First, dsRNA or shRNA expressed from an RNAi expression vector is recognized by Dicer and degraded into 21-23 nucleotide siRNAs. The siRNAs are then incorporated into an RNAi target complex called the RNA-Induced Silencing Complex (RISC), where the RISC and siRNAs complex contains a sequence that is complementary to the siRNA sequence. Binds to mRNA and degrades mRNA. The target mRNA is cleaved at the center of the region complementary to the siRNA. Finally, the target mRNA is rapidly degraded and the protein expression level decreases. The most potent siRNA duplex is known to be a 21 nucleotide long sequence with two uridine residue overhangs at each 3 'end of the 19 bp duplex (Elbashir SM et al. Genes and Dev, 15, 188-200 (2001)).

  In general, the target sequence on the mRNA can be selected from a cDNA sequence corresponding to the mRNA. However, the present invention is not limited to this region.

  siRNA molecules can be designed based on criteria well known in the art. For example, as the target segment of the target mRNA, a continuous 15-30 base, preferably 19-25 base segment, preferably starting with AA, TA, GA or CA can be selected. The GC ratio of siRNA molecules is 30-70%, preferably 35-55%. Alternatively, the target sequence of RNAi can be appropriately selected according to the description of Ui-Tei K. et al. ((2004) Nucleic Acids Res. 32, 936-948).

  In order to introduce siRNA into a cell, a method of linking synthesized siRNA to plasmid DNA and introducing it into a cell, a method of annealing double-stranded RNA, and the like can be employed.

  The present invention can also use shRNA to produce RNAi effects. shRNA is called short hairpin RNA, and is an RNA molecule having a stem-loop structure so that a partial region of a single strand forms a complementary strand with another region.

  shRNA can be designed so that a part thereof forms a stem-loop structure. For example, if the sequence of a certain region is set as sequence A and the complementary strand to sequence A is set as sequence B, these sequences are linked in the order of sequence A, spacer, and sequence B so that they are present in one RNA strand. Design to be 45-60 bases in length. The length of the spacer is not particularly limited.

  Sequence A is the sequence of a partial region of the target monoterpene glucosylase gene, and the target region is not particularly limited, and any region can be a candidate. The length of the sequence A is 19 to 25 bases, preferably 19 to 21 bases.

  Furthermore, the present invention can inhibit the expression of monoterpene glycosides using microRNA. MicroRNA (miRNA) is a single-stranded RNA with a length of about 20-25 bases that exists in cells, and is considered to have a function to regulate the expression of other genes (non-coding RNA) It is a kind of. miRNAs are produced as a nucleic acid that forms a hairpin structure that is produced by being processed when transcribed into RNA and suppresses the expression of a target sequence.

  Since miRNA is also an inhibitory nucleic acid based on RNAi, it can be designed and synthesized according to shRNA or siRNA.

  RNAi expression vectors are easily created using a commercially available DNA / RNA synthesizer (for example, Applied Biosystems 394) based on the pMuniH1 plasmid, pSINsi vector (Takara Bio), pSIF1-H1 (System Bioscience), etc. can do. An example of an expression vector for RNAi is, for example, pSPB1876 (International Publication WO2004 / 071467), but is not limited thereto. Expression vectors for RNAi can be outsourced to third parties such as Cosmo Bio Inc., Takara Bio Inc., Invitrogen Inc., and Promega Inc.

A method for producing a plant in which the expression of a monoterpene glycoside enzyme is suppressed may include the following steps.
(1) Introducing an RNAi expression vector (for example, siRNA expression vector or miRNA expression vector) for a monoterpene glycoside into a host plant or a part thereof

  The method of introducing an expression vector for RNAi into a host plant is the same as the method described in the item “3. Non-human transformant having a high monoterpene glycoside content”. A host plant is a whole plant or a part of a plant organ (eg, leaf, petal, stem, root, seed, etc.), plant tissue (eg epidermis, phloem, soft tissue, xylem, vascular bundle, fence-like shape) Tissue, spongy tissue, etc.) or plant culture cells, or various forms of plant cells (eg, suspension culture cells), protoplasts, leaf sections, callus, etc. The types of plants are the same as those described in the item “3.

(2) Step of growing the transformed plant obtained in the step (1) The host plant used in the step (1) is a plant body such as a plant organ, plant tissue, plant cell, protoplast, leaf section or callus. If it is a part of the above, the transformant may be grown in an appropriate environment until a complete plant is formed. For a method of growing a complete plant from a part of the plant, reference can be made to the following literature: Biochemical Experimental Method 41 Introduction to Plant Cell Engineering Society Publication Center ISBN 4-7622-1899-5.

  By cultivating the plant in which the expression of the monoterpene glucosylase gene thus obtained is suppressed, monoterpene aglycone can be efficiently produced.

6． Processed products of plants in which the expression of monoterpene glycoside enzyme gene is suppressed At present, not only fresh flowers (for example, soil-growing plants, potted plants, cut flowers, etc.), but also processed products of fresh flowers as products for plant appreciation Sold. Plants in which the expression of the monoterpene glucosylase gene is suppressed have a strong fragrance, and thus are very useful as materials for such fresh flower processed products. Therefore, as another embodiment of the present invention, a plant (for example, a fresh flower, a cut flower) or a part thereof (for example, a leaf, a petal, a stem, a root, a seed, Processed products such as bulbs). Examples of the processed product include, but are not limited to, pressed flowers, dried flowers, preserved flowers, material flowers, and sealed resin products.

7. Extract of plant in which expression of monoterpene glucosidase is suppressed and use thereof In another embodiment, the present invention also provides a plant extract in which the expression of monoterpene glucosylase is suppressed in another embodiment. Provide an extract. Plants with suppressed expression of monoterpene glucosylase have higher monoterpene aglycone content than their wild type, so the extract contains a higher concentration of monoterpene aglycone. Conceivable.
The method for extracting the extract is the same as the method for extracting the extract of the transformant of the present invention described above.
The extract thus obtained can be used in accordance with a conventional method, for example, for applications such as production of foods, fragrances, pharmaceuticals, and industrial raw materials (raw materials such as cosmetics and soaps).

In another embodiment, the present invention also provides foods, fragrances, medicines and industrial raw materials (raw materials such as cosmetics and soaps) containing the extract. Preparation of foods, fragrances, medicines and industrial raw materials containing the extract is according to a conventional method. As described above, foods, fragrances, pharmaceuticals, industrial raw materials, etc. containing plant extracts in which the expression of monoterpene glycosides is suppressed use plants in which the expression of monoterpene glycosides is suppressed. The monoterpene aglycon produced in this way is contained.
The kind and composition of the food, flavor, medicine, industrial raw material and the like of the present invention are the same as those described in the previous item “4. Extract of transformant and use thereof”.

8． Method for Screening Plants with High Terpene Glycoside Content or Plants with High Monoterpene / Aglycon Content The present invention provides a method for screening plants with high monoterpene / aglycone content. Specifically, the method includes the following steps (1) to (3).
(1) Step of extracting mRNA from a test plant (2) Hybridization under high stringency conditions with the mRNA or cDNA prepared from the mRNA and a polynucleotide comprising a base sequence complementary to the polynucleotide of the present invention A step of hybridizing with a polynucleotide to soy (3) a step of detecting said hybridization

  The step (1) can be performed by extracting mRNA from the test plant. The site of the test plant from which mRNA is extracted is not particularly limited, but is preferably a petal. When mRNA is extracted, cDNA may be prepared from mRNA by reverse transcription.

  In step (2), the above-extracted mRNA is hybridized under highly stringent conditions using a polynucleotide or oligonucleotide having a base sequence complementary to the polynucleotide of the present invention as a probe or primer. It can be carried out. High stringency conditions are as already described. The polynucleotide or oligonucleotide is preferably 5 to 500 bp, more preferably 10 to 200 bp, and still more preferably 10 to 100 bp in length. Polynucleotides or oligonucleotides can be easily synthesized using various automatic synthesizers (for example, AKTA oligopilot plus 10/100 (GE Healthcare)), or can be synthesized by a third party (for example, Promega or It can also be entrusted to Takara).

  When a polynucleotide comprising a nucleotide sequence complementary to the polynucleotide of the present invention is used as a probe in the step (2), the step (3) is performed by ordinary Southern blotting or Northern blotting (Sambrook, Fritsch and Maniatis, “ Molecular Cloning: A Laboratory Manual ”2nd Edition (1989), Cold Spring Harbor Laboratory Press), microarray (Affymetrix; see US Pat. Nos. 6,045,996, 5,925,525, and 5,858,659), TaqMan PCR (Sambrook, Fritsch and Maniatis, “Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press), or Fluorescent In Situ Hybridization (FISH) (Sieben VJ et al., (2007-06). IET Nanobiotechnology 1 (3 ): 27-35) and other hybridization detection methods. On the other hand, when a polynucleotide comprising a base sequence complementary to the polynucleotide of the present invention is used as a primer in step (2), step (3) performs PCR amplification reaction, and the obtained amplification product is electrically converted. Hybridization can be detected by analysis by electrophoresis or sequencing (Sambrook, Fritsch and Maniatis, “Molecular Cloning: A Laboratory Manual” 2nd Edition (1989), Cold Spring Harbor Laboratory Press).

  The plant body in which more hybridization was detected expresses more protein having the activity to glycosylate the monoterpene compound than other plant bodies, so the terpene glycoside content is high. Is predicted.

  On the other hand, the plant body detected with less hybridization has a higher monoterpene / aglycone content because the expression of the protein having the activity to glycosidate the monoterpene compound is lower than that of other plant bodies. It is expected to give off a strong fragrance during flowering.

  EXAMPLES Hereinafter, although this invention is demonstrated more concretely using an Example, the scope of the present invention is not limited by these Examples.

[Example 1] Cloning of U-derived UGT85 homolog CsUGT30 For the cDNA library of Cha (Yabukita varieties) (Non-Reference 10) Screening was attempted using the full-length sequence as a probe. Using about 300,000 pfu of phage containing the above cDNA library, the above UGT85A3 and UGT85A1 gene-specific primer sets (CACC-NdeI-UGT85A3-Fw (SEQ ID NO: 3) and XhoI-stop-UGT85A3-Rv (SEQ ID NO: 4) and NdeI-AtUGT85A1-Fw (SEQ ID NO: 5) and BamHI-AtUGT85A1-Rv (SEQ ID NO: 6)) were used as screening probes for screening by plaque hybridization.
That is, screening by plaque hybridization was performed using the fragments amplified by the following primer sets 1 and 2 as screening probes.

Primer set 1
CACC-NdeI-UGT85A3-Fw:
5'-CACC CATATG GGATCCCGTTTTGTTTC -3 '(SEQ ID NO: 3)
XhoI-stop-UGT85A3-Rv:
5'- CTCGAG TTACGTGTTAGGGATCTTTC -3 '(SEQ ID NO: 4)
Primer set 2
NdeI-AtUGT85A1-Fw
5'-CACCCATATGGGATCTCAGATCATTCATAAC-3 '(SEQ ID NO: 5)
BamHI-AtUGT85A1-Rv
5'-GGATCCTTAATCCTGTGATTTTTGTCCCAAAAG-3 '(SEQ ID NO: 6)

The probe was labeled by PCR using a non-radioisotope DIG-nucleic acid detection system (Roche Diagnostics) according to the conditions recommended by the manufacturer. At this time, a PCR reaction solution containing 1 μl of template DNA (about 1 pg of the above-described UGT85A3 expression plasmid), 1 × Taq buffer (TakaRa Bio), 0.2 mM dNTPs, 0.2 pmol / μl of each primer, and rTaq polymerase 1.25 U was used. This PCR reaction solution was reacted at 94 ° C. for 5 minutes, followed by 30 cycles of 94 ° C. for 1 minute, 52 ° C. for 1 minute, and 72 ° C. for 2 minutes, and finally treated at 72 ° C. for 5 minutes. Primers and unreacted dNTPs were removed from this PCR product with a Mini Quick Spin column (Roche), and this was used as a screening probe.
Library screening and positive clone detection were performed using a non-radioisotope DIG-nucleic acid detection system (Roche Diagnostics) and following the manufacturer's recommended method. The hybridization reaction was carried out overnight at 37 ° C. in 5 × SSC containing 30% formamide, and the membrane was washed at 55 ° C. for 20 minutes using 5 × SSC and 1% SDS. About 500,000 plaques were screened. After the secondary screening, cDNA sequences were obtained from the obtained positive clones by a primer walking method using synthetic oligonucleotide primers using DNA Sequencer model 3100 (Applied Biosystems). The obtained cDNA sequence was subjected to homology analysis by the Blastx program (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to obtain a cha UGT gene (CsUGT).

  One of the obtained UGTs, CsUGT30 (CDS sequence: SEQ ID NO: 1, amino acid sequence: SEQ ID NO: 2), shows high sequence similarity to UGTs of cassava (Manihot esculenta) cyanide glycosides, UGT85K4 and UGT85K5. (For UGT85K4 and UGT85K5, see Non-Patent Document 14.)

In order to clarify the monoterpene glycosylation activity of the obtained CsUGT30, this enzyme was expressed in E. coli. CsUGT30 was amplified using the following CsUGT30 gene-specific primer set (SEQ ID NO: 7 and SEQ ID NO: 8).

CsUGT30 amplification primer set
XhoI-CsUGT30-Fw: 5'-CACCCTCGAGATGGGTAGCAGAAAGCAG-3 '(SEQ ID NO: 7)
BglII-CsUGT30-Rv: 5'- AGATCTTTAGTATTGCTCACAATAGTGAAGAGC -3 '(SEQ ID NO: 8)

The PCR reaction solution (50 μl) was composed of 1 μl of the above-mentioned cha-derived cDNA, 1 × ExTaq buffer (TaKaRaBio), 0.2 mM dNTPs, each primer 0.4 pmol / μl, and ExTaq polymerase 2.5U. The PCR reaction was carried out at 94 ° C. for 3 minutes, followed by amplification for 30 cycles of 94 ° C. for 1 minute, 50 ° C. for 1 minute, and 72 ° C. for 2 minutes. The PCR product was electrophoresed on a 0.8% agarose gel and stained with ethidium bromide. As a result, an amplification band having a size of about 1.4 kb estimated from each template DNA was obtained.
These PCR products were subcloned into the pENTR-TOPO Directional vector (Invitrogen) by the method recommended by the manufacturer. Using DNA Sequencer model 3100 (Applied Biosystems), it was confirmed that there was no mutation due to PCR in the inserted fragment by the primer walking method using synthetic oligonucleotide primers.
Thereafter, the plasmid was inserted into pET15b (Novagen), an E. coli expression vector from Invitrogen, by a method recommended by the manufacturer to prepare an E. coli expression plasmid, and CsUGT30 was expressed as a fusion protein with HisTag as follows.
Next, E. coli BL21 (DE3) strain was transformed according to a conventional method. The obtained transformant was cultured with shaking at 37 ° C overnight in 4 ml of LB medium (10 g / l typtone pepton, 5 g / l yeast extract, 1 g / l NaCl) containing 50 µg / ml ampicillin. did. 4 ml of the culture solution that reached the stationary phase was inoculated into 80 ml of the medium having the same composition and cultured with shaking at 37 ° C. When the cell turbidity (OD600) reached approximately 0.5, IPTG with a final concentration of 0.5 mM was added, and the mixture was cultured with shaking at 18 ° C. for 20 hr.
All the following operations were performed at 4 ° C. The cultured transformants are collected by centrifugation (5,000 × g, 10 min), and Buffer S [20 mM HEPES buffer (pH 7.5), 20 mM imidazole, 14 mM β-mercaptoethanol] 1 ml / g cell Was added and suspended. Subsequently, ultrasonic crushing (15 sec × 8 times) was performed, and centrifugation (15,000 × g, 15 min) was performed. The obtained supernatant was recovered as a crude enzyme solution. The crude enzyme solution was loaded on His SpinTrap (GE Healthcare) equilibrated with Buffer S and centrifuged (70 × g, 30 sec). After washing with Buffer, the protein bound to the column was eluted stepwise with 5 ml each of Buffer S containing 100 mM and 500 mM imidazole. Each elution fraction was substituted with 20 mM HEPES buffer (pH 7.5) and 14 mM β-mercaptoethanol using Microcon YM-30 (Amicon) (dialysis magnification 1000 times).

  After purification with HisTag column, expression was confirmed by SDS-PAGE (FIG. 1). In lane “C-30” in FIG. 1, the arrow and the square frame indicate the eluted HisTag-fused CsUGT30 protein. On the other hand, lane “C-15” is a negative control, cell lysate obtained from E. coli BL21 (DE3) strain transformed with pET15b empty vector without insert was purified by HisTag column, and the purified product was purified by SDS- PAGE.

Next, the reactivity with monoterpene was examined by LC-MS analysis using CsUGT30 protein.
Standard enzyme reaction conditions are as follows. A reaction solution (2 mM UDP-glucose, 0.2 mM sugar receptor substrate, 100 mM potassium phosphate buffer (pH 7.5), purified CsUGT30 enzyme solution 25 μl) was prepared to 50 μl with distilled water, and reacted at 30 ° C. for 1 hour.
LC-MS analysis was performed on 5 μl of the enzyme reaction solution under the following conditions.

LC condition
Column: CAPCELL PAK C18-UG120 (2.0 mmI.D. × 150 mm)
Mobile phase: A: Water (with + 0.05% formic acid), B: Acetonitrile gradient: Linear concentration gradient from 15% to 90% B concentration for 15 minutes: 0.2 ml / min
Column oven: 40 ° C

MS condition
ESI (negative mode)
SIM mode: (m / z 315, 338, 361, 363, 331, 354, 377, 429 etc)

When the recombinant CsUGT30 protein was reacted with linalool or geraniol, monoglucosylated glycosides were detected in both reactions (FIG. 2). In Fig. 2, linalool glycoside (standard product), reaction solution of linalool and CsUGT30, reaction solution of linalool and heat-denatured CsUGT30, geraniol glycoside (standard product), geraniol and CsUGT30 in order from the top. The LC-MS analysis result about a reaction liquid is shown. In FIG. 2, a square frame indicates a product (monoterpene glucoside) by CsUGT30.
On the other hand, no new product was observed in the reaction between the heat-denatured recombinant CsUGT30 protein and linalool. From the above results, it was shown that CsUGT30 has an activity to glycosylated monoterpene.

[Example 2] Cloning of tea-derived UGT85 homolog CsUGT-C1 The above-mentioned UGT85A3 and UGT85A1 gene-specific primer sets (CACC-NdeI-UGT85A3- Fw (SEQ ID NO: 3) and XhoI-stop-UGT85A3-Rv (SEQ ID NO: 4) and NdeI-AtUGT85A1-Fw (SEQ ID NO: 5) and BamHI-AtUGT85A1-Rv (SEQ ID NO: 6)) screening probes As in Example 1, screening by plaque hybridization was performed.

  After screening, cDNA sequences were obtained from the obtained positive clones by a primer walking method using synthetic oligonucleotide primers using DNA Sequencer model 3100 (Applied Biosystems). The obtained cDNA sequence was analyzed by homology using the Blastx program (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to obtain another cha UGT gene CsUGT-C1 (CDS sequence: SEQ ID NO: 9, amino acid) Sequence: SEQ ID NO: 10) was obtained.

  CsUGT-C1 showed 47% sequence identity at the DNA level (CDS sequence comparison) to CsUGT30 and 28% sequence identity at the amino acid level.

In order to clarify the monoterpene glycosylation activity of the obtained CsUGT-C1, this enzyme was expressed in E. coli. CsUGT-C1 was amplified using the following CsUGT-C1 gene-specific primer set (SEQ ID NO: 11 and SEQ ID NO: 12).

CsUGT-C1 amplification primer set
CACC-NdeI-CsUGT-C1-Fw: 5'-CACCCATATGGCTAAGCTTCATTTCTTC-3 '(SEQ ID NO: 11)
CsUGT-C1-BamHI-Stop-Rv: 5'-GGATCCTTATGAACTCATTTCTTGTATCAGAG-3 '(SEQ ID NO: 12)

The PCR reaction is the same as that of Example 1 except that the CsUGT-C1 gene-specific primer set is used.
The PCR product was electrophoresed on a 0.8% agarose gel and stained with ethidium bromide. As a result, an amplification band having a size of about 1.4 kb estimated from each template DNA was obtained.
This PCR product was subcloned into the pENTR-TOPO Directional vector (Invitrogen) by the method recommended by the manufacturer. Using DNA Sequencer model 3100 (Applied Biosystems), it was confirmed that there was no mutation due to PCR in the inserted fragment by the primer walking method using synthetic oligonucleotide primers.
Thereafter, the plasmid was inserted into pET15b (Novagen) of Invitrogen's Escherichia coli expression vector by the method recommended by the manufacturer to prepare an E. coli expression plasmid.
In the same manner as in Example 1, CsUGT-C1 was expressed in Escherichia coli as a fusion protein with HisTag, and the protein was recovered and purified.

  After purification on the HisTag column, expression was confirmed by SDS-PAGE (FIG. 3, M: marker, C: control). In FIG. 3, the square frame indicates the eluted HisTag-fused CsUGT-C1 protein. In the control (lane C in FIG. 3), a cell lysate obtained from Escherichia coli transformed with the pET15b empty vector without insert was purified with a HisTag column, and the purified product was subjected to SDS-PAGE.

Next, the reactivity with monoterpene was examined by LC-MS analysis using CsUGT-C1 protein.
The reaction conditions for CsUGT-C1 protein and monoterpene and the conditions for LC-MS analysis of the reaction solution are the same as in Example 1.

When the recombinant CsUGT-C1 protein was reacted with linalool or geraniol, monoglucosylated glycosides were detected in both reactions (FIG. 4). In Fig. 4, linalool glycoside (standard product), reaction solution of linalool and CsUGT-C1, reaction solution of linalool and heat-denatured CsUGT-C1, geraniol glycoside (standard product), geraniol in order from the top The LC-MS analysis result about the reaction liquid of CsUGT-C1 is shown.
In FIG. 4, a square frame indicates a product (monoterpene glucoside) by CsUGT-C1.
On the other hand, no new product was observed in the reaction between the heat-denatured recombinant CsUGT-C1 protein and linalool. From the above results, it was shown that CsUGT-C1 has an activity of glycosylated monoterpene.

  According to the present invention, it is possible to transfer a single molecule of glucose to monoterpenes in vitro or by introducing the gene of the present invention into a host cell, and development of a new functional food material or secondary metabolism. The present invention is extremely useful in that terpene glycosides that can contribute to molecular breeding and the like can be more easily produced or reduced.

Sequence number 3: Synthetic DNA
Sequence number 4: Synthetic DNA
Sequence number 5: Synthetic DNA
Sequence number 6: Synthetic DNA
Sequence number 7: Synthetic DNA
Sequence number 8: Synthetic DNA
Sequence number 11: Synthetic DNA
Sequence number 12: Synthetic DNA

Claims (10)

The protein according to any one selected from the group consisting of the following (a) to (c).
(A) a protein comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10;
(B) in the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10, deletion 1-47 amino acid substitutions, insertions, and / or addition of one amino acid sequence, and distribution of the monoterpene compound having a hydroxy group A protein having an activity of glycation ;
(C) a protein having an amino acid sequence having a sequence identity of 90% or more with respect to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10 and having an activity to glycosylate a monoterpene compound having a hydroxy group   2. The protein according to claim 1, wherein the monoterpene compound is geraniol or linalool. A polynucleotide selected from the group consisting of the following (a) to ( d ).
(A) a polynucleotide comprising the base sequence of SEQ ID NO: 1 or SEQ ID NO: 9;
(B) a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10;
(C) In the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10 , a monoterpene compound consisting of an amino acid sequence in which 1 to 47 amino acids are deleted, substituted, inserted and / or added and having a hydroxy group A polynucleotide encoding a protein having an activity of glycation;
(D) a protein having an amino acid sequence having a sequence identity of 90% or more with respect to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 10 and having an activity to glycosylate a monoterpene compound having a hydroxy group Polynucleotide encoding   A non-human transformant into which the polynucleotide according to claim 3 is introduced.   5. The transformant according to claim 4, wherein the polynucleotide is inserted into an expression vector.   The transformant according to claim 4, which is a plant. 5. A method for producing a protein having an activity of glycosylating a monoterpene compound having a hydroxy group, wherein the non-human transformant according to claim 4 is cultured. And protein according to claim 1, UDP-sugar and, by reacting a monoterpene compound having a hydroxy group include the step of glycosides of the monoterpene compounds, a manufacturing method of a monoterpene glycoside. 9. The method of claim 8 , wherein the UDP-sugar is UDP-glucose. 9. The method according to claim 8 , wherein the monoterpene compound is geraniol or linalool.